The impact of gut microbiome-targeted therapy on liver enzymes in patients with nonalcoholic fatty liver disease: an umbrella meta-analysis
The DOI matches its Crossref record; 95 of the 96 references it cites were found in a registry or an index.
Abstract
Context: Nonalcoholic fatty liver disease (NAFLD) is considered the leading cause of chronic liver disease worldwide. To date, no confirmed medication is available for the treatment of NAFLD. Previous studies showed the promising effects of gut microbiome–targeted therapies; however, the results were controversial and the strength of the evidence and their clinical significance remained unclear. Objectives: This umbrella study summarizes the results of meta-analyses investigating the effects of probiotics, prebiotics, and synbiotics on liver enzymes in the NAFLD population. Data Source: A comprehensive search of the PubMed, Scopus, Web of Science, and Cochrane Library databases was done up to December 20, 2022, to find meta-analyses on randomized control trials reporting the effects of gut microbial therapy on patients with NAFLD. Data Extraction: Two independent investigators extracted data on the characteristics of meta-analyses, and any discrepancies were resolved by a third researcher. The AMSTAR2 checklist was used for evaluating the quality of studies. Data Analysis: A final total of 15 studies were included in the analysis. Results showed that microbiome-targeted therapies could significantly reduce levels of alanine aminotransferase (ALT; effect size [ES], −10.21; 95% confidence interval [CI], −13.29, −7.14; P < 0.001), aspartate aminotransferase (AST; ES, −8.86; 95%CI, −11.39, −6.32; P < 0.001), and γ-glutamyltransferase (ES, −5.56; 95%CI, −7.92, −3.31; P < 0.001) in patients with NAFLD. Results of subgroup analysis based on intervention showed probiotics could significantly reduce levels of AST (ES, −8.69; 95%CI, −11.01, −6.37; P < 0.001) and ALT (ES, −9.82; 95%CI, −11.59, −8.05; P < 0.001). Synbiotics could significantly reduce levels of AST (ES, −11.40; 95%CI, −13.91, −8.88; P < 0.001) and ALT (ES, −11.87; 95%CI, −13.80, −9.95; P < 0.001). Prebiotics had no significant effects on AST and ALT levels (ES, −2.96; 95%CI, −8.12, 2.18, P = 0.259; and ES, −4.69; 95%CI, −13.53, 4.15, P = 0.299, respectively). Conclusion: Gut microbiome–targeted therapies could be a promising therapeutic approach in the improvement of hepatic damage in patients with NAFLD. However, more studies are needed to better determine the best bacterial strains, duration of treatment, and optimum dosage of gut microbiome–targeted therapies in the treatment of the NAFLD population. Systematic Review Registration: PROSPERO registration no. CRD42022346998.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Gut microbial therapy by administration of probiotics, synbiotics and prebiotics may alleviate the medical condition in specific disorders, for example reduction of C-reactive protein50, low-density lipoprotein (LDL)51, alanine aminotransferase and aspartate aminotransferase52 and insulin resistance53 among non-alcoholic fatty liver disease (NAFLD).”
From Association between attention-deficit/hyperactivity disorders and intestinal disorders: A systematic review and Meta-analysis (2025) · cites this paper as [52]
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Shea, B. J., Reeves, B. C., Wells, G., Thuku, M., Hamel, C., Moran, J., Moher, D., Tugwell, P., Welch, V., Kristjansson, E., et al. (2017) · BMJ · doi:10.1136/bmj.j4008 · Cited by 10,636
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.006 · Cited by 10,578
Sterne, J. A. C., Sutton, A. J., Ioannidis, J. P. A., Terrin, N., Jones, D. R., Lau, J., Carpenter, J., Rucker, G., Harbord, R. M., Schmid, C. H., et al. (2011) · BMJ · doi:10.1136/bmj.d4002 · Cited by 7,709
The Human Intestinal Microbiome in Health and Disease
Lynch, S. V., & Pedersen, O. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1600266 · Cited by 3,637
Nonalcoholic Fatty Liver Disease: A Systematic Review
Rinella, M. E. (2015) · JAMA · doi:10.1001/jama.2015.5370 · Cited by 2,267
The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis
Riazi, K., Azhari, H., Charette, J. H., Underwood, F. E., King, J. A., Afshar, E. E., Swain, M. G., Congly, S. E., Kaplan, G. G., & Shaheen, A.-A. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00165-0 · Cited by 2,246
Non-alcoholic fatty liver disease - a global public health perspective
Younossi, Z. M. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.033 · Cited by 2,149
Intestinal barrier function: molecular regulation and disease pathogenesis
Groschwitz, K. R., & Hogan, S. P. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.05.038 · Cited by 1,775
Lactic Acid Permeabilizes Gram-Negative Bacteria by Disrupting the Outer Membrane
Alakomi, H.-L., Skyttä, E., Saarela, M., Mattila-Sandholm, T., Latva-Kala, K., & Helander, I. M. (2000) · Applied and Environmental Microbiology · doi:10.1128/aem.66.5.2001-2005.2000 · Cited by 1,093
Cited by
Amini-Salehi, E., Letafatkar, N., Norouzi, N., Joukar, F., Habibi, A., Javid, M., Sattari, N., Khorasani, M., Farahmand, A., Tavakoli, S., et al. (2024) · Archives of Medical Research · doi:10.1016/j.arcmed.2024.103043 · Cited by 171
Self-citationSaeed, H., Díaz, L. A., Gil‐Gómez, A., Burton, J. P., Bajaj, J. S., Romero‐Gómez, M., Arrese, M. A., Arab, J. P., & Khan, M. Q. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0811 · Cited by 91
“Nevertheless, extensive evidence exists with regards to the effect of pre-, pro-, and synbiotics on reduction in liver enzymes, while the effect on liver fibrosis and liver steatosis is not always observed or reported 78 – 81 .”
Recent advances in therapeutic probiotics: insights from human trials
Cho, M.-Y., Eom, J.-H., Choi, E.-M., Yang, S., Lee, D., Kim, Y.-Y., Kim, H.-S., & Hwang, I. (2025) · Clinical Microbiology Reviews · doi:10.1128/cmr.00240-24 · Cited by 58
Yogesh, M., Patel, M., Gandhi, R. B., Patel, A. M., & Kidecha, K. N. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-01935-y · Cited by 46
“[73–76] Several limitations should be considered when interpreting the findings of this systematic review and meta-analysis.”
Vakilpour, A., Amini‐Salehi, E., Moghadam, A. S., Keivanlou, M., Letafatkar, N., Habibi, A., Hashemi, M., Eslami, N., Zare, R., Norouzi, N., et al. (2024) · Nutrition and Diabetes · doi:10.1038/s41387-024-00281-7 · Cited by 35
“SCFAs trigger the secretion of GLP-1 by activating G-protein-coupled receptors (GPR) [82].”
BackgroundSelf-citationGuney-Coskun, M., & Başaranoğlu, M. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i43.4682 · Cited by 32
“Recent meta-analyses have shown that gut microbiome-targeted therapies significantly reduce liver enzyme levels, suggesting a promising avenue to prevent hepatocyte damage in MASLD patients[38].”
Chen, D., Wang, Y., Yang, J., Ou, W., Lin, G., Zeng, Z., Lu, X., Chen, Z., Zou, L., Tian, Y., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1343755 · Cited by 32
Hashemi, S. M. H., Kheirandish, M., Rafati, S., Ghazalgoo, A., Amini‐Salehi, E., Keivanlou, M., Abbaszadeh, S., Saberian, P., & Rahimi, A. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02378-5 · Cited by 29
“Central to MetS is insulin resistance, often driven by visceral obesity, which promotes a pro-inflammatory state and endothelial dysfunction [13–17].”
Self-citationQin, W., Wang, S., Min, Y., Liu, X., Fang, J., Lang, J., & Chen, M. (2025) · BMC Women s Health · doi:10.1186/s12905-025-03599-1 · Cited by 29
Amini‐Salehi, E., Mahapatro, A., Korsapati, R. R., Korsapati, A. R., Jain, S. M., Babaeizad, A., Mohammadi, S., Rashidian, P., Hashemi, M., Dave, T., et al. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.05.017 · Cited by 26
Self-citationRole of gut microbiota and immune cells in metabolic-associated fatty liver disease: clinical impact
Alisi, A., McCaughan, G. W., & Grønbæk, H. (2024) · Hepatology International · doi:10.1007/s12072-024-10674-6 · Cited by 23
“In two meta-analyses, authors showed that gut microbial therapy significantly reduced serum CRP, TNF, and liver enzymes (ALT, AST, and γ-glutamyltransferase) in NAFLD patients and in sub-group analysis, this was seen both for probiotics and synbiot-ics [91, 92].”
Gut microbiota interventions in type 2 diabetes mellitus: An umbrella review of glycemic indices
Keivanlou, M., Amini‐Salehi, E., Sattari, N., Hashemi, M., Saberian, P., Prabhu, S. V., Javid, M., Mirdamadi, A., Heidarzad, F., Bakhshi, A., et al. (2024) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2024.103110 · Cited by 23
Self-citationKeivanlou, M., Amini‐Salehi, E., Hassanipour, S., Zare, R., Mohammadi‐Vajari, E., Hashemi, M., Salari, A., & Porteghali, P. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998284844240102110559 · Cited by 22
Self-citationThe Gut-Liver Axis: Molecular Mechanisms and Therapeutic Targeting in Liver Disease
Ma, L., Wang, H., Jin, Q., Sun, Z., Yu, S., & Zhang, Y. (2025) · International Journal of General Medicine · doi:10.2147/ijgm.s551494 · Cited by 21
Habibi, A., Letafatkar, N., Sattari, N., Nobakht, S., Rafat, Z., Moghadam, S. S., Mirdamadi, A., Javid, M., Jamilian, P., Hassanipour, S., et al. (2024) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2024.11.011 · Cited by 20
Self-citationAmini‐Salehi, E., Nayak, S. S., Maddineni, G., Mahapatro, A., Keivanlou, M., Moghadam, S. S., Vakilpour, A., Aleali, M. S., Joukar, F., Hashemi, M., et al. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000001740 · Cited by 18
“Although more research is required to establish the ef fi cacy of these compounds in preventing and treating NAFLD, many studies have demonstrated a link between microbial modulation and enhancement in patients ’ liver enzymes, lipid pro fi le, steatosis, and other factors [29 – 35] .”
MethodSelf-citationEl‐Sehrawy, A. A. M. A., Jafari, M. T., Zwamel, A. H., Rashidian, P., Ballal, S., Kalia, R., Nanda, A., Maharana, L., Javankiani, S., Hashemi, M., et al. (2025) · Journal of Health Population and Nutrition · doi:10.1186/s41043-025-00926-y · Cited by 17
Self-citationExploring public interest in gut microbiome dysbiosis, NAFLD, and probiotics using Google Trends
Pezzino, S., Sofia, M., Mazzone, C., Litrico, G., Agosta, M., Greca, G. L., & Latteri, S. (2024) · Scientific Reports · doi:10.1038/s41598-023-50190-5 · Cited by 16
Alotaibi, A. S., Mahapatro, A., Mirchandani, M., Jala, S. R. A., Mohanty, E., Marsool, M. D. M., Jeanty, H., Devulapally, P., Jain, S. M., Keivanlou, M., et al. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000003019 · Cited by 14
Self-citationNayak, S. S., Amini‐Salehi, E., Ulrich, M. T., Sahli, Y., Fleischman, M., Patel, M., Naeiji, M., Maghsoodifar, H., Douki, S. A. H. S., Alotaibi, A., et al. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000003034 · Cited by 14
Self-citationNg, R. W. Y., Chen, Z., Yang, L., Wong, O. W. H., Leung, A. S. Y., Tsui, K. W., Kwok, N. M. W., Tang, L. H. Y., Cheung, P. M. H., Chan, P. K. S., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-04303-x · Cited by 13
“…and prebiotics may alleviate the medical condition in specific disorders, for example reduction of C-reactive protein 50 , low-density lipoprotein (LDL) 51 , alanine aminotransferase and aspartate aminotransferase 52 and insulin resistance 53 among non-alcoholic fatty liver disease (NAFLD).”
Yang, Y., Liu, Z., Lin, B., HUANG, Y. ‐., Deng, H., Yang, X., Zeng, L., Yan, J., & Xu, W. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01732-6 · Cited by 13
“Hepatic lipid accumulation disrupts insulin’s suppression of gluconeogenesis, as evidenced by the association between microbiome-tar-geted therapies and reduced liver fat content [49].”
Agyeman, K. B., Shafi, N., Contreras, R., Parackal, V., Shah, D. N., Gurram, A., Keetha, N. R., & Ameen, D. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e42736 · Cited by 9
Advances in molecular epidemiology of diabetic retinopathy: from genomics to gut microbiomics
Huang, Y., Rao, S., Sun, X., & Liu, J. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10383-9 · Cited by 7
Ding, S., Hong, Q., Yao, Y., Gu, M., Cui, J., Li, W., Zhang, J., Zhang, C., Jiang, J., & Hu, Y. (2024) · Food & Function · doi:10.1039/d4fo02561j · Cited by 6
Aleali, M. S., Mahapatro, A., Maddineni, G., Paladiya, R. D., Jeanty, H., Mohanty, E., Mirchandani, M., Jahanshahi, A., Devulapally, P., Alizadehasl, A., et al. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000003140 · Cited by 6
Self-citationDecoding the mechanistic basis of liver–muscle communication in health and disease
Gamil, N. M., Elsayed, H. A., Salah, E. T., Mostafa, H. A., El‐Shiekh, R. A., Ghaiad, H. R., & Eitah, H. E. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05015-3 · Cited by 6
“Muscle mitochondrial dysfunction reduces fatty acid oxidation, increases intramyocellular lipid intermediates, and activates inflammatory and proteolytic pathways (e.g., NF-κB, FoxO, and MuRF1/Atrogin-1) (Shaikh et al. 2025).”
InfluentialAssociation between breast cancer risk factors and blood microbiome in patients with breast cancer
An, J., Kwon, H., Oh, S., & Kim, Y. J. (2025) · Scientific Reports · doi:10.1038/s41598-025-90180-3 · Cited by 6
“Microecological changes in the human body have been linked to chronic diseases, such as breast and liver disease 36,37 .”
Maddineni, G., Obulareddy, S. J., Paladiya, R. D., Korsapati, R. R., Jain, S., Jeanty, H., Vikash, F., Tummala, N., Shetty, S., Ghazalgoo, A., et al. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002276 · Cited by 5
“While there isn ’ t a speci fi c treatment for NAFLD, microbial therapies such as probiotics, prebiotics, and synbiotics are thought to offer a novel therapeutic approach by modifying the intestinal microbiota [32,33] .”
BackgroundThe Role of Microbiome in Cardiovascular Health: Insights for Primary Care Interventions.
Pascucci, J. A., Hasbun, P. G., Lerma, R. O., Nogueyra, S. V., Bernal, M. B. N., Milani, V., Rietmann, L. M. F., Alvarez, S. M., & Diaz, J. S. (2024) · PubMed Central · doi:10.7759/cureus.70311 · Cited by 5
Higher relative fat mass was associated with a higher prevalence of gallstones in US adults
Xie, S., Ma, S., Chen, X., Li, F., & Li, D. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-03715-3 · Cited by 5
Dinevari, M. F., Abbasian, S., Sarmadian, A. J., Vaezi, T., Vaezi, T., Nikniaz, Z., & Riazi, A. R. (2026) · European journal of medical research · doi:10.1186/s40001-026-03901-3 · Cited by 4
Acierno, C., Caturano, A., Barletta, F., Rinaldi, L., Sasso, F. C., Adinolfi, L. E., & Nevola, R. (2026) · Nutrients · doi:10.3390/nu18111765 · Cited by 4
“The main clinical principle that follows is conservative: microbiome-targeted interventions in MASLD may be discussed as adjunctive strategies within a broader metabolic framework, but none currently justifies being presented as a disease-modifying therapy in its own right [17,117].”
InfluentialAmini‐Salehi, E., Hasanpour, M., Alotaibi, A. S., Rashidian, P., Hashemi, S. M. H., Nasrollahizadeh, A., Letafatkar, N., Saberian, P., Amani‐Beni, R., & Shanbehzadeh, N. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000003089 · Cited by 4
Self-citationLv, M., Shafagh, G., & Yu, S. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-03789-z · Cited by 4
“Syn-biotics, which combine probiotics (beneficial bacteria) and prebiotics (non-digestible fibers that promote the growth of beneficial bacteria), help restore a healthy gut microbiota balance to improve cardiovascular risk factors [56–59].”
MICROBIOTA INTESTINAL COMO NOVO ALVO TERAPÊUTICO NA CARDIOLOGIA
Goulart, E. T. V., Ferreira, A. D. S., Evangelista, E. X. S., Neto, G. F. D. S., Malizan, J. M., Oliveira, L. D. R., de Almeida, P. C., de Lima, T. M. N. A. T., Perino, D. P., & da Rosa, J. P. S. (2025) · EPITAYA eBooks · doi:10.47879/ed.ep.2025936p281 · Cited by 2
Nilo, D., di Lorenzo, G., Montagna, M. L., Nevola, R., Marrone, A., Sasso, F. C., & Caturano, A. (2026) · Biocell · doi:10.32604/biocell.2026.081324 · Cited by 2
“Although heterogeneity among studies persists, cumulative evidence suggests that microbiota-targeted interventions can reduce hepatic steatosis, inflammation, and metabolic dysregulation, reinforcing the therapeutic relevance of restoring eubiosis along the gut–liver axis [146].”
The gut microbiome and nonalcoholic fatty liver disease: prospects for drug therapy
Teplyuk, D. A., Levina, O. N., Pavlov, C. S., Sorokoletov, S. M., Pashkova, E. Y., As, A., Bolshakov, S. A., & Shutov, E. V. (2024) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-230-10-178-187 · Cited by 1
Microbiota and fatty liver disease: Potential candidate for therapeutic intervention
Eslami, M., Naderian, R., Tarahomi, M., Babaeizad, A., Amini, P., & Pouya, P. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27370-4.00026-3 · Cited by 1
Pam, P., Safari, M., Hojati, A., Zarrin, R., & Faghfouri, A. H. (2026) · Journal of Paediatrics and Child Health · doi:10.1111/jpc.70344 · Cited by 1
“This finding is broadly consistent with other systematic reviews focusing on MASLD, which have also reported that probiotic interventions can significantly lower ALT levels [48–50].”
Moszak, M., Kaczmarczyk, M., Kręgielska-Narożna, M., Łoniewski, I., Skonieczna‐Żydecka, K., Szulińska, M., & Bogdański, P. (2026) · Nutrition · doi:10.1016/j.nut.2026.113325 · Cited by 1
(2025) · The Egyptian Journal of Hospital Medicine · doi:10.21608/ejhm.2025.425845
Yadav, A., Dadhich, S., Saini, V. K., Bhati, R. S., & Mitrolia, B. (2025) · Egyptian Liver Journal · doi:10.1186/s43066-025-00441-z
Non-alcoholic fatty liver disease and periodontitis – clinical and pathogenetic relationships
Ахмедов, В. А. (2025) · Medical alphabet · doi:10.33667/2078-5631-2025-13-12-15
Ei-alkoholiperäinen rasvamaksa ja suolistomikrobisto
Liukonen, J. (2024) · Jyväskylä University Digital Archive (University of Jyväskylä)
Mulyono, A., Muthmainnah, Sasmitaninghidayah, W., & Agustin, I. A. (2025) · International Journal of Design & Nature and Ecodynamics · doi:10.18280/ijdne.201217
“Recent studies have shown that PZA may induce liver injury through multiple biological mechanisms, including mitochondrial dysfunction, disturbances in lipid metabolism, and increased oxidative stress within hepatocytes [8].”
Mahapatro, A., Jeanty, H., Jala, S. R. A., Somu, K. P., Madineni, G., Mohanty, E., Marsool, M. D. M., Shamsi, P., Namin, M. S., Abbaszadeh, S., et al. (2026) · Medicine · doi:10.1097/md.0000000000048629
Self-citationLin, K., Chen, B., Zhang, X., Fan, M., Wang, P., Wang, Y., Cheng, X., Ma, Z., Chen, X., Xue, X., et al. (2026) · Journal of Medical Microbiology · doi:10.1099/jmm.0.002156
“Gut microbiota dysbiosis in diabetic patients is associated with multiple factors, including the use of antidiabetic medication [24], hypertension [25], lipid profiles [26] and impaired liver function [27, 28].”
Jiang, Y., Shi, Y., & Cao, J. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1940415
“This study confirmed that probiotics and synbiotics can significantly reduce ALT and AST levels in patients with MASLD/NAFLD, which is largely consistent with the findings of previous systematic reviews (57–59).”
InfluentialVenkatesh, V., Yodoshi, T., Seetharaman, K., & Anushree, N. (2026) · European Journal of Pediatrics · doi:10.1007/s00431-026-07548-4
“Meta-analyses have reported reductions in transaminase levels with probiotics and synbiotics [32, 33].”
Неалкогольная жировая болезнь печени и пародонтит – клинико-патогенетические взаимосвязи
Адильевич, А. В. (2025) · Medical alphabet
Metadata
- Authors
- Amini-Salehi, E., Hassanipour, S., Keivanlou, M.-H., Shahdkar, M., Orang Goorabzarmakhi, M., Vakilpour, A., Joukar, F., Hashemi, M., Sattari, N., Javid, M., & Mansour-Ghanaei, F.
- Affiliations
- Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences , Rasht, Iran
- Guilan University of Medical Sciences (IR)
- School of Medicine, Guilan University of Medical Sciences , Rasht, Iran
- Hormozgan University of Medical Sciences (IR)
- ORCID
- Venue
- Nutrition Reviews
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-08-07
- Volume
- 82
- Issue
- 6
- Pages
- 815-830
- ISSN
- 0029-6643 (ISSN-L)
- 1753-4887
- OpenAlex
- W4385621532
- Cited by
- 42
- References
- 96
- Citations by year
- 2026: 8 · 2025: 18 · 2024: 16
- FWCI
- 1.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nutrition Reviews (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- non-alcoholic fatty liver disease, probiotics, prebiotics, synbiotics, liver enzymes, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase, NAFLD treatment, evidence quality assessment, AMSTAR 2, subgroup analysis
- MeSH terms
- Gastrointestinal Microbiome, Alanine Transaminase, Aspartate Aminotransferases, Humans, Liver, Probiotics, Prebiotics, Synbiotics, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.